EMEA-002399-PIP01-18-M01
Key facts
| Invented name |
Hepcludex
|
| Active substance |
Bulevirtide
|
| Therapeutic area |
Infectious diseases
|
| Decision number |
P/0270/2022
|
| PIP number |
EMEA-002399-PIP01-18-M01
|
| Pharmaceutical form(s) |
Powder for solution for injection
|
| Condition(s) / indication(s) |
Treatment of chronic hepatitis D infection
|
| Route(s) of administration |
Subcutaneous use
|
| Contact for public enquiries |
Gilead Sciences International Ltd.
Tel. +44 (0)1223 897 300 |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|